OncoMatch/Clinical Trials/NCT06185972
Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer
Is NCT06185972 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Definity and Sonalleve Focused Ultrasound Device for breast cancer.
Treatment: Definity · Sonalleve Focused Ultrasound Device — The objective of this study is to demonstrate the efficacy and response of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline
Patients having received anthracycline or taxane based chemotherapy within the past 5 days
Cannot have received: taxane
Patients having received anthracycline or taxane based chemotherapy within the past 5 days
Lab requirements
Kidney function
Creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional upper limit of normal. Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis [excluded].
Cardiac function
Severe cardiovascular, cardiac disease or unstable hemodynamics including myocardial infarction within six months, unstable angina, congestive heart failure, cardiac shunts, cardiac arrhythmia and cardiac pacemaker [excluded]. Known QT prolongation = (QTc > 450ms for men or >470ms for women) with cardiac impairment if ECG is requested as per SOC [excluded]. Contraindication to perflutren including subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation like cisapride, erythromycin, tricyclic antidepressants, Class IA and III antiarrhythmic agents and some antipsychotics like haloperidol, droperidol, quetiapine, thioridazine, ziprasidone [excluded].
Creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional upper limit of normal. Severe cardiovascular, neurological, renal or hematological chronic disease [excluded]. Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify